<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003257114
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZITHROMAX 500 MG POWDER FOR IV INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACIA UPJOHN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACIA UPJOHN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER ITALY S.R.I
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zithromax contains the active substance azithromycin, an azalide antibiotic that belongs to the group of antibiotics known as &ldquo;macrolides&rdquo;.&nbsp; Azithromycin blocks the growth of susceptible bacteria.</p><p>&nbsp;</p><p>Zithromax is indicated for <strong>adults </strong>and <strong>children</strong> over <strong>16 years</strong> who require initial intravenous administration (in vain) to treat the following infections (caused by microorganisms which are sensitive to azithromycin):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; community acquired <strong>pneumonia </strong>(inflammation of the lungs) including legionellosis (caused by <em>Legionella pneumophila</em>)</p><p><strong>ovarian inflammation</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You will not be administered Zithromax </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to azithromycin, erythromycin, other antibiotics known as &ldquo;macrolides&rdquo; or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>This medicine is only available in hospitals. Therefore, this medicine will only be administered to you under the strict supervision of qualified medical staff.</p><p>&nbsp;</p><p><strong>Before</strong> you are administered Zithromax, advise the doctor of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have ever had liver problems or if you are or have recently taken other medicines that can cause liver problems (see &ldquo;Other medicines and Zithromax&rdquo;). In these cases, exercise caution before starting treatment with Zithromax;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated with ergotamine or its derivatives (see &ldquo;Other medicines and Zithromax&rdquo;);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from kidney problems (kidney failure);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a heart rhythm disorder. Zithromax can also cause mild heart rhythm abnormalities, although these have been fatal in some cases (see section 4, &ldquo;Possible side effects&rdquo;).</p><p>This medicine must therefore be used with caution:</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with congenital heart rhythm abnormalities, with a very slow heartbeat (bradycardia), heart rhythm disorders (arrhythmia) or serious heart problems (severe heart failure);</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients treated with other medicines that can affect heart rhythm, such as quinidine, procainamide, dofetilide, amiodarone, sotalol (medicines used to treat heart rhythm abnormalities), cisapride (medicine used to treat reflux of the contents of the stomach into the oesophagus), terfenadine (medicine used to treat allergies), pimozide (medicine used to treat mental disorders), citalopram (medicine used to treat depression), moxifloxacin, levofloxacin, chloroquine (antibiotics);</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with low blood potassium or magnesium levels;</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the elderly and women.</p><p>&nbsp;</p><p>Tell your doctor if any of the following conditions occur or worsen <strong>during</strong> treatment with Zithromax (see also section 4, &ldquo;Possible side effects&rdquo;):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions, including severe skin reactions, which can also affect other organs and cause fever. In cases of allergic reactions, stop taking Zithromax <strong>immediately</strong> and talk to your doctor;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of liver problems such as sudden onset of weakness, yellowing of the skin or mucous membranes, dark urine, bleeding easily, brain symptoms (such as confusion, altered level of consciousness or coma). Stop taking Zithromax <strong>immediately</strong> and talk to your doctor, who will run tests to check the condition of your liver;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting or irritability in your child (for infants aged under 42 days) that appear after feeding. This medicine can cause shrinkage of one part of the stomach. If these symptoms occur, talk to the doctor treating your child <strong>immediately</strong>;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of new infections or persistence of symptoms of the infection being treated. This could be caused by bacteria that are not susceptible to Zithromax (resistant bacteria) or by micro-organisms other than bacteria (fungal infections);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Onset of diarrhoea, which may be mild, but can cause death in some cases (fatal colitis). Diarrhoea can occur with the use of almost all antibiotics, including Zithromax. This is due to alteration of the normal bacterial flora of the intestine, allowing excessive growth of a bacterium known as <em>Clostridium difficile</em>. In cases of diarrhoea, your doctor will place you under strict monitoring, as <em>Clostridium difficile</em> infection may occur up to two months after stopping treatment with this medicine;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; appearance or worsening of muscle weakness and fatigue, i.e. the symptoms of myasthenia gravis.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>There is currently no information on the efficacy and safety of Zithromax powder for solution for infusion in children under 16 years.</p><p>&nbsp;</p><p>Other medicines and Zithromax</p><p>Tell your doctor or pharmacist if you, or your child, are taking, have recently taken or might take any other medicine.</p><p>&nbsp;</p><p>Tell your doctor if you, or your child, are taking one of the following medicines, because caution is required:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin (used to treat heart failure). When taken at the same time as Zithromax, the dose of digoxin must be carefully controlled;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colchicine (used to treat gout and familial Mediterranean fever);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; zidovudine (medicine against HIV infection);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ergotamine (medicine used to treat headaches). You should not take Zithromax at the same time as ergotamine because blood circulation disorders can occur, especially in the fingers and toes (convulsive ergotism);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statins (medicines to reduce levels of fats in the blood). Taking statins at the same time as Zithromax can cause muscle cell breakdown (rhabdomyolysis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (medicine against organ transplant rejection). When taken at the same time as Zithromax, the dose of ciclosporin must be carefully controlled;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral anticoagulants such as coumarin (e.g. warfarin). When taken at the same time as Zithromax, the anticoagulant effect of these medicines may increase.</p><p><s>&nbsp;</s></p><p>Zithromax must not be taken with other medicines that affect heart rhythm (see &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>ZithromaxYour doctor will decide if you should be given this medicine during pregnancy, only after making sure that the benefits outweigh the potential risks.</p><p><em>&nbsp;</em></p><p><em>Breast-feeding</em></p><p>Zithromax passes into breast milk. Therefore, if you are breast-feeding, your doctor will only prescribe this medicine for you when absolutely necessary.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>It is not known whether this medicine affects the ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Zithromax</strong><strong> contains sodium</strong></p><p>This medicine contains 114 mg of sodium (main component of cooking/table salt) in each vial. This is equivalent to 5,7% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>This medicine may be prepared with a solution that contains sodium. This should be taken into additional consideration if you are on a low salt (sodium) diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is only available in hospitals. Therefore, this medicine will be administered intravenously under the strict supervision of qualified medical staff.</p><p>The appropriate dose will be established by the doctor depending on the disease, but the doses are, generally, recommended as follows:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>To treat pneumonia</strong></p><p>The recommended dose is 500 mg of powder for solution for infusion, once per day, for at least 2 days.</p><p>Once the intravenous treatment is finished, the doctor will prescribe 500 mg of azithromycin to be taken orally once per day for up to 7-10 days.</p><p>The doctor will decide the best time to change from intravenous to oral administration.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>To treat ovarian inflammation</strong></p><p>The recommended dose is 500 mg of powder for solution for infusion, once per day, for 1-2 days.</p><p>Once the intravenous treatment is finished, the doctor will prescribe 250 mg of azithromycin to be taken orally once per day for up to 7 days.</p><p>The doctor will decide the best time to change from intravenous to oral administration.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>There is currently no information on the efficacy and safety of Zithromax powder for solution for infusion in children under 16 years.</p><p>Children over 16 years can take an adult dose.</p><p>&nbsp;</p><p><strong>Specific patient populations</strong></p><p>If you are elderly, have mild to moderate liver problems or kidney problems, your doctor can prescribe the same doses as above.</p><p>&nbsp;</p><p><strong>If more Zithromax is administered than prescribed</strong></p><p>It is very unlikely that a higher dose of Zithromax will be administered than that prescribed because the doctor will carry out checks on you or your child during the treatment.</p><p>However, in case a higher dose of Zithromax is administered than that prescribed, the doctor will administer appropriate supportive therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>The following side effects have occurred after taking Zithromax.</strong></p><p>&nbsp;</p><p><strong>STOP</strong> using Zithromax <strong>immediately </strong>if you or your child experience any of the following side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction (anaphylactic shock)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, tongue and throat, making it impossible to swallow and breathe (angioedema), increased sensitivity of the skin and mucous membranes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe inflammation of the final part of the intestine, known as the colon, caused by overgrowth of a bacterium known as <em>Clostridium difficile</em> (pseudomembranous colitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin rash associated with an increase in the number of a type of white blood cell known as eosinophils, symptoms that may affect one or more organs and cause fever (DRESS) (frequency rare)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red and scaly skin rash with formation of pustules and vesicles (exanthematous pustulosis) (frequency rare)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe acute hypersensitivity reaction involving the skin and mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) (frequency not known)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe liver problems (severe liver failure), which can sometimes result in death</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden, massive death of liver cells (fulminant hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; toxic liver reaction with cell death</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia due to destruction of red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden loss of consciousness (fainting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (pancreatitis)</p><p>&nbsp;</p><p>Talk to your doctor if you experience any of the following side effects:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in blood bicarbonate levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the amount of a type of white blood cell known as lymphocytes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of a type of white blood cell known as eosinophils</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of a type of white blood cell known as basophils</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of a type of white blood cell known as monocytes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of a type of white blood cell known as neutrophils</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the vagina and/or mouth by <em>Candida</em> (a fungus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection by micro-organisms known as &ldquo;fungi&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection by micro-organisms known as &ldquo;bacteria&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pharyngitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastroenteritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rhinitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of white blood cells (leukopaenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of one type of white blood cell known as neutrophils (neutropaenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in one type of white blood cell known as eosinophils (eosinophilia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease or lack of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in sensitivity of different parts of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; distortion or lowering of the sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enhanced perception of heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flushes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleeds (epistaxis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; production of air in the intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty or pain when swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; belching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased saliva production</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dermatitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; backache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neck pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when urinating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the kidneys</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal, heavy and continued bleeding from the vagina</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; testicle problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; malaise</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the legs and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in liver function tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of bilirubin in the blood (a substance produced by the liver)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of urea in the blood (a substance produced by the liver)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of creatinine in the blood (a substance produced by the muscles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood potassium and sodium levels (mineral salts)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of chloride in the blood (a mineral salt)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in amount of glucose (a sugar) in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the number of platelets in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in the amount of bicarbonate in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; complications after medical or surgical operations</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alteration of liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowish colouring of the skin and mucous membranes (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heightened sensitivity of the skin to sunlight (photosensitivity)</p><p>&nbsp;</p><p><strong>Frequency not known</strong> (cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of platelets in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sensitivity of any area of the body to stimulus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggressiveness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delirium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive motor activity and agitation (restlessness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; total or partial loss of the sense of smell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; total loss of the sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe muscle weakness (myasthenia gravis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; faster heartbeat, caused by a specific heart rhythm disorder (arrhythmia) known as &ldquo;torsades de pointes&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbances in normal heart rate known as arrhythmia (e.g. ventricular tachycardia, QT interval prolongation), which are shown on a test known as an &ldquo;electrocardiogram&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lowering of blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tongue discolouration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe kidney problems (acute kidney failure, interstitial nephritis)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system.</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date stated on the box and on the vial after &ldquo;EXP.&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is azithromycin (as azithromycin dihydrate).</p><p>Each vial contains 500&nbsp;mg of azithromycin (equivalent to 524.1mg azithromycin dihydrate).</p><p>&nbsp;</p><p>The other ingredients are: Citric acid, sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The powder is contained in a single-use 10 mL glass vial with a bromobutyl rubber stopper and aluminium seal.
Each package contains 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Italia S.r.l.</p><p>Via Isonzo, 71</p><p>04100 Latina, Italy</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>&nbsp;</p><p>Manufacturing and Packaging:<br />Pharmacia Upjohn Company LLC, Kalamazoo, United States<br /><br />Labelling, secondary packaging, and release:<br />Fareva Amboise, Amboise, France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يحتوي زيثروماكس على المادة الفعالة أزيثرومايسين، وهي مضاد حيوي أزاليدي ينتمي إلى مجموعة من المضادات الحيوية تُعرف باسم &quot;الماكروليدات&quot;. يمنع أزيثرومايسين نمو البكتيريا الحساسة له.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصف زيثروماكس <strong>للبالغين </strong>و<strong>الأطفال</strong> الذين تبلغ أعمارهم أكثر من <strong>١٦ عامًا</strong> الذين يحتاجون إلى تلقي علاج أولي عن طريق الوريد (في الوريد) لعلاج حالات العدوى التالية (التي تسببها الكائنات الدقيقة الحساسة لأزيثرومايسين):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الالتهاب الرئوي </strong>(التهاب الرئتين) المكتسب من المجتمع بما في ذلك داء الفيلقيّات (الذي تسببه الفيلقية المستروحة (لوجينيلا نيموفيلا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المبيض</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>موانع استعمال زيثروماكس </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه أزيثرومايسين، أو إريثرومايسين، أو المضادات الحيوية الأخرى التي تعرف باسم &quot;الماكروليدات&quot;، أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زيثروماكس</strong></p><p dir="RTL">هذا الدواء متوفر في المستشفيات فقط. وبالتالي، لن يتم إعطاؤك هذا الدواء إلا تحت إشراف دقيق من قبل طاقم طبي مؤهل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قبل</strong> إعطائك زيثروماكس، أخبر طبيبك بما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو سبق لك أن عانيت من مشكلات في الكبد أو إذا كنت تتناول أو تناولت مؤخرًا أدوية أخرى قد تسبب مشكلات في الكبد (انظر قسم &quot;التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية&quot;). في هذه الحالات، توخ الحذر قبل بدء العلاج بزيثروماكس؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بإرجوتامين أو مشتقاته (انظر قسم &quot;التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية&quot;)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكلى (الفشل الكلوي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب في ضربات القلب. يمكن أن يسبب زيثروماكس أيضًا اختلالات خفيفة في ضربات القلب، إلا أنها كانت مميتة في بعض الحالات (انظر القسم ٤، &quot;الأعراض الجانبية&quot;).</p><p dir="RTL">لذلك، يجب توخي الحذر عند استخدام هذا الدواء:</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى المصابين باختلالات خلقية في ضربات القلب، أو بطء شديد في ضربات القلب (بطء القلب)، أو اضطرابات ضربات القلب (اضطراب النظم) أو مشكلات قلبية خطيرة (فشل القلب الشديد)؛</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى الذين يتلقون العلاج بأدوية أخرى يمكن أن تؤثر على نظم القلب، مثل كينيدين، بروكايناميد، دوفيتيليد، أميودارون، سوتالول (أدوية تستخدم لعلاج اختلالات ضربات القلب)، سيسابريد (دواء يستخدم لعلاج ارتجاع محتويات المعدة إلى المريء)، تيرفينادين (دواء يستخدم لعلاج حالات الحساسية)، بيموزيد (دواء يستخدم لعلاج الاضطرابات العقلية)، سيتالوبرام (دواء يستخدم لعلاج الاكتئاب)، موكسيفلوكساسين، ليفوفلوكساسين، كلوروكين (مضادات حيوية)؛</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى الذين لديهم انخفاض في مستويات البوتاسيوم والمغنيسيوم في الدم؛</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع المسنين والسيدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا ظهرت أي من الحالات التالية أو تفاقمت <strong>أثناء</strong> العلاج بزيثروماكس (انظر أيضًا القسم ٤، &quot;الأعراض الجانبية&quot;):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة، بما في ذلك التفاعلات الجلدية الشديدة التي قد تؤثر أيضًا على أعضاء أخرى وتسبب الحمى. في حالة حدوث تفاعلات حساسية، توقف <strong>فورًا</strong> عن استخدام زيثروماكس وتحدث إلى طبيبك؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض لوجود مشكلات في الكبد، مثل بدء الشعور بالضعف بصورة مفاجئة، اصفرار الجلد أو الأغشية المخاطية، لون البول الداكن، سهولة الإصابة بنزيف، أعراض متعلقة بالدماغ (مثل الارتباك، أو تغير مستوى الوعي، أو الغيبوبة). توقف عن أخذ زيثروماكس <strong>فورًا</strong> وتحدث إلى الطبيب الذي سيخضعك لاختبارات لفحص حالة كبدك؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة طفلك بالقيء أو التهيج (بالنسبة للرضع الذين يقل عمرهم عن ٤٢ يومًا) الذي يظهر بعد الرضاعة. يمكن أن يتسبب هذا الدواء في انكماش جزء من المعدة. إذا حدثت هذه الأعراض، فتحدث <strong>فورًا </strong>مع الطبيب المعالج لطفلك؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض حالات عدوى جديدة أو استمرار أعراض العدوى التي يتم علاجها. يمكن أن يرجع السبب في ذلك إلى الإصابة ببكتيريا غير حساسة لزيثروماكس (بكتيريا مقاومة) أو كائنات مجهرية بخلاف البكتيريا (عدوى فطرية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدء الإصابة بالإسهال، الذي قد يكون خفيفًا ولكن قد يسبب الوفاة في بعض الحالات (التهاب القولون المميت). يمكن أن يحدث الإسهال مع استخدام جميع المضادات الحيوية تقريبًا، بما في ذلك زيثروماكس، وذلك بسبب حدوث تغير في النبيت البكتيري الطبيعي الموجود في الأمعاء، مما يسمح بالنمو المفرط لبكتيريا تعرف بالمطثية العسيرة (كلوستريديوم ديفيسيل). في حالة حدوث إسهال، سوف يقوم طبيبك بوضعك تحت المراقبة الدقيقة، نظرًا لأن عدوى المطثية العسيرة (كلوستريديوم ديفيسيل) يمكن أن تظهر بعد إيقاف العلاج بهذا الدواء بما يصل إلى شهرين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أو تفاقم الضعف العضلي والإرهاق، أي أعراض الوهن العضلي الوبيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">في الوقت الحالي، لا توجد معلومات حول فعالية وسلامة زيثروماكس مسحوق لتحضير محلول للتسريب مع الأطفال بعمر أقل من ١٦ عامًا.</p><p dir="RTL">&nbsp;</p><p><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت أنت أو طفلك تتناولان أو تناولتما مؤخرًا أو قد تتناولان أي دواء آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت أنت أو طفلك تتناولان أحد الأدوية التالية، نظرًا لأنه يتعين توخي الحذر في هذه الحالة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين (يُستخدم لعلاج فشل القلب). عند تناوله بالتزامن مع زيثروماكس، يجب ضبط جرعة ديجوكسين بعناية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولشيسين (يُستخدم لعلاج النقرس وحمى البحر الأبيض المتوسط العائلية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفودين (دواء مضاد لعدوى فيروس نقص المناعة البشرية (HIV))؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرجوتامين (دواء لعلاج الصداع). ينبغي ألا تتناول زيثروماكس بالتزامن مع إرجوتامين لأن ذلك قد يسبب حدوث اضطرابات في الدورة الدموية، خاصة في أصابع اليدين والقدمين (التسمم الإرجوتي التشنجي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات (أدوية لخفض مستويات الدهون في الدم). يمكن أن يؤدي تناول الستاتينات بالتزامن مع زيثروماكس إلى تحلل الخلايا العضلية (انحلال الربيدات)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (دواء مضاد لرفض الجسم للعضو المزروع). عند تناول سيكلوسبورين بالتزامن مع زيثروماكس، يجب ضبط جرعة سيكلوسبورين بعناية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات تجلط الدم التي يتم تناولها عن طريق الفم مثل الكومارين (على سبيل المثال، وارفارين). عند تناول هذه الأدوية بالتزامن مع زيثروماكس، يمكن أن يسبب ذلك زيادة أثرها المضاد لتجلط الدم.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL">يجب عدم تناول زيثروماكس مع الأدوية الأخرى التي تؤثر على ضربات القلب (انظر قسم &quot;الاحتياطات عند استعمال زيثروماكس&quot;).</p><p dir="RTL">&nbsp;</p><p>الحمل والرضاعة</p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الحمل</em></p><p dir="RTL">زيثروماكسزيثروماكسسيقرر طبيبكِ ما إذا كان ينبغي أن تتناولي هذا الدواء أثناء الحمل، فقط بعد التأكد من أن الفوائد تفوق المخاطر المحتملة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الرضاعة الطبيعية</em></p><p dir="RTL">يمر زيثروماكس إلى لبن الثدي. ولذلك، إذا كنتِ ترضعين رضاعة طبيعية، فسوف يصف لكِ طبيبكِ هذا الدواء فقط في حالة الضرورة القصوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زيثروماكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المعروف إذا ما كان هذا الدواء يؤثر على القدرة على القيادة أو استخدام الآلات أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات زيثروماكس</strong></p><p dir="RTL"><strong>يحتوي زيثروماكس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على ١١٤ ملجم من الصوديوم (المكون الأساسي لملح الطهي/الطعام) في كل قارورة. وهذا يعادل ٥٫٧% من الحد الأقصى الموصى به من المدخول الغذائي اليومي من الصوديوم للبالغين.</p><p dir="RTL">يمكن تحضير هذا الدواء بمحلول يحتوي على الصوديوم. ينبغي أن يؤخذ هذا بمزيد من الاعتبار، إذا كنت تتبع نظامًا غذائيًا منخفض الملح (الصوديوم).</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">هذا الدواء متوفر في المستشفيات فقط. وبالتالي، سيتم إعطاء هذا الدواء عن طريق الوريد تحت الإشراف الدقيق من قبل طاقم طبي مؤهل.</p><p dir="RTL">سيحدد الطبيب الجرعة الملائمة وفقًا للمرض، ولكن الجرعات الموصى بها بشكل عام هي كما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لعلاج الالتهاب الرئوي</strong></p><p dir="RTL">الجرعة الموصى بها هي ٥٠٠ ملجم من المسحوق المخصص لتحضير محلول للتسريب، مرة واحدة في اليوم، لمدة يومين على الأقل.</p><p dir="RTL">بمجرد انتهاء تلقي العلاج عن طريق الوريد، سيصف الطبيب جرعة قدرها ٥٠٠ ملجم من أزيثرومايسين ليتم تناولها عن طريق الفم مرة واحدة في اليوم لمدة تصل إلى ٧-١٠ أيام.</p><p dir="RTL">سيحدد الطبيب الوقت الأفضل للتغيير من الاستعمال عن طريق الوريد إلى الاستعمال عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لعلاج التهاب المبيض</strong></p><p dir="RTL">الجرعة الموصى بها هي ٥٠٠ ملجم من المسحوق المخصص لتحضير محلول للتسريب، مرة واحدة في اليوم، لمدة يوم إلى يومين.</p><p dir="RTL">بمجرد انتهاء تلقي العلاج عن طريق الوريد، سيصف الطبيب جرعة قدرها ٢٥٠ ملجم من أزيثرومايسين ليتم تناولها عن طريق الفم مرة واحدة في اليوم لمدة تصل إلى ٧ أيام.</p><p dir="RTL">سيحدد الطبيب الوقت الأفضل للتغيير من الاستعمال عن طريق الوريد إلى الاستعمال عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL">في الوقت الحالي، لا توجد معلومات حول فعالية وسلامة زيثروماكس مسحوق لتحضير محلول للتسريب مع الأطفال بعمر أقل من ١٦ عامًا.</p><p dir="RTL">يمكن للأطفال بعمر أكبر من ١٦ عامًا أخذ جرعات البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الفئات الخاصة من المرضى</strong></p><p dir="RTL">إذا كنت من المسنين أو تعاني من مشكلات كبدية خفيفة إلى متوسطة الشدة أو مشكلات كلوية ، يمكن أن يصف لك طبيبك الجرعات نفسها المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زيثروماكس</strong></p><p dir="RTL">من المستبعد جدًا أن يتم إعطاء زيثروماكس بجرعة أكبر من الجرعة الموصوفة، نظرًا لأن الطبيب سيخضعك لفحوصات أنت أو طفلك أثناء العلاج.</p><p dir="RTL">مع ذلك، إذا تم إعطاء زيثروماكس بجرعة أكبر من الجرعة الموصوفة، فسيقدم لك الطبيب العلاج الداعم الملائم.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حدثت الأعراض الجانبية التالية بعد أخذ زيثروماكس.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف</strong> عن استخدام زيثروماكس<strong> فورًا</strong> إذا أصبت أنت أو طفلك بأي من الأعراض الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية خطير (صدمة تأقية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، واللسان، والحلق، الأمر الذي يجعل من البلع والتنفس شيئًا مستحيلًا (تورم وعائي)، زيادة حساسية الجلد والأغشية المخاطية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب شديد في الجزء الأخير من الأمعاء، المعروف بالقولون، بسبب النمو المفرط لبكتيريا تسمى المطثية العسيرة (كلوستريديوم ديفيسيل) (التهاب القولون الغشائي الكاذب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; طفح جلدي شديد مصحوب بزيادة في عدد نوع من خلايا الدم البيضاء يعرف باليوزينيات، وأعراض قد تؤثر على عضو واحد أو أكثر وتسبب الحمى (التفاعلات الدوائية المصحوبة بكثرة اليوزينيات وأعراض جهازية (DRESS)) (معدل التكرار نادر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; طفح جلدي أحمر ومتقشر مع تكون بثرات وحويصلات (البثار الطفحي) (معدل التكرار نادر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; تفاعل فرط حساسية شديد وحاد يصيب الجلد والأغشية المخاطية (متلازمة ستيفنز-جونسون، تقشر الأنسجة المتموتة البشروية التسممي، البقع الحمراء عديدة الأشكال) (معدل التكرار غير معروف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات كبدية شديدة (فشل الكبد الشديد)، يمكن أن تؤدي إلى الوفاة في بعض الأحيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت مفاجئ وجسيم لخلايا الكبد (التهاب الكبد الخاطف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل كبدي سام مصحوب بموت الخلايا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم الناتج عن تدمير خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي المفاجئ (الإغماء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مع طبيبك إذا أصبت بأحد الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في مستويات البيكربونات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في كمية نوع من خلايا الدم البيضاء يدعى الليمفاويات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية نوع من خلايا الدم البيضاء يدعى اليوزينيات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية نوع من خلايا الدم البيضاء يدعى القعدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية نوع من خلايا الدم البيضاء يدعى وحيدات النواة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية نوع من خلايا الدم البيضاء يدعى العدلات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المهبل و/أو الفم بسبب المبيضات (الكانديدا) (نوع من الفطريات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى بكائنات دقيقة تدعى &quot;الفطريات&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى بكائنات دقيقة تدعى &quot;البكتيريا&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات التنفسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء (نقص الكريات البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد نوع من خلايا الدم البيضاء يدعى العدلات (قلة العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في نوع من خلايا الدم البيضاء يدعى اليوزينيات (كثرة اليوزينيات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أو فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في حساسية أجزاء مختلفة من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حاسة التذوق أو انخفاضها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الإحساس بضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس (ضيق النفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف (الرعاف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتاج هواء في الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة البلع أو الشعور بألم عند البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إفراز اللعاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط العرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العنق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عند التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالكليتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غير عادي وغزير ومستمر من المهبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الخصيتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوعك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرهاق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الساقين والقدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبارات وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية البيليروبين في الدم (مادة ينتجها الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية اليوريا في الدم (مادة ينتجها الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية الكرياتينين في الدم (مادة تنتجها العضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في مستويات البوتاسيوم والصوديوم في الدم (الأملاح المعدنية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية الكلوريد في الدم (ملح معدني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية الجلوكوز (سكر) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية البيكربونات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاعفات بعد الإجراءات الطبية أو العمليات الجراحية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار لون الجلد والأغشية المخاطية (اليرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد تجاه أشعة الشمس (الحساسية للضوء)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معدل التكرار غير معروف </strong>(لا يمكن تقديره من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حساسية أي منطقة من الجسم تجاه المحفزات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوانية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهذيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهلاوس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط الحركي والتهيج (التململ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان كلي أو جزئي لحاسة الشم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان كلي لحاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف شديد في العضلات (الوهن العضلي الوبيل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصمم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة سرعة ضربات القلب، يسببها اضطراب معين في ضربات القلب (اضطراب ضربات القلب) يسمى &quot;ضفيرة النتوءات&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في معدل ضربات القلب الطبيعي تعرف باسم اضطراب نظم القلب (مثل، تسرع القلب البطيني، إطالة فترة QT)، تظهر في اختبار يسمى &quot;مخطط كهربية القلب&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم (انخفاض ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في لون اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات شديدة في الكلى (الفشل الكلوي الحاد، التهاب الكلية الخلالي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ القومي</p><p dir="RTL">بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em>مركز الاتصال: ١٩٩٩٩</p><p dir="RTL">&middot;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp; </em><em>الرجاء الاتصال بالسلطات المختصة ذات الصلة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p>احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم زيثروماكسهذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة وعلى القارورة بعد كلمة &quot;.EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تخزنه عند درجة حرارة أعلى من ٣٠ درجة مئوية</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة هي أزيثرومايسين (في صورة أزيثرومايسين ثنائي الهيدرات).</p><p dir="RTL">تحتوي كل قارورة على ٥٠٠ ملجم من أزيثرومايسين (بما يكافئ ٥٢٤٫١ ملجم من أزيثرومايسين ثنائي الهيدرات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: حمض الستريك، هيدروكسيد الصوديوم.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يوجد المسحوق في قارورة زجاجية للاستخدام مرة واحدة ١٠ مل بسدادة من مطاط البروموبيوتيل ومانع تسرب من الألومنيوم.</p><p dir="RTL">تحتوي كل عبوة على قارورة واحدة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Italia S.r.l, Via Isonzo 71, 04100 Latina, Italy، ايطاليا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">التصنيع والتعبئة:</p><p dir="RTL">Pharmacia Upjohn Company LLC, Kalamazoo, United States، الولايات المتحدة الأمريكية<br /><br />وضع الملصقات والتعبئة الثانوية وإطلاق الدفعات:</p><p dir="RTL">Fareva Amboise, Amboise, France، فرنسا</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر/تشرين الأول ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zithromax I.V.
500 mg powder for solution for infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:

Active substance:
Azithromycin dihydrate	524.1 mg
equivalent to Azithromycin base	500 mg

Excipient with known effects: 
ZITHROMAX 500 mg powder for solution for infusion contains 114 mg sodium in each vial.

For the full list of excipients, see section 6.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ZITHROMAX powder for solution for infusion is indicated in the treatment of community-acquired pneumonia caused by susceptible organisms, including <em>Legionella pneumophila</em>, in patients who require an initial therapy intravenously.</p><p>&nbsp;</p><p>ZITHROMAX powder for solution for infusion is indicated in the treatment of pelvic inflammatory disease caused by susceptible organisms, in patients who require an initial therapy intravenously.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the treatment of community-acquired pneumonia, the recommended dosage for an adult is 500 mg of ZITHROMAX powder for solution for infusion in a single daily dose intravenously for at least two days. Intravenous therapy must be followed by oral therapy with a dose of 500 mg once-daily dosing regimen for a total period of treatment of 7-10 days. The time it takes to make the transition to oral therapy must be decided by the physician depending on the clinical response.</p><p>In the treatment of pelvic inflammatory disease, the recommended dosage for an adult is 500 mg of ZITHROMAX powder for solution for infusion in a single daily dose intravenously for one or two days. Intravenous therapy must be followed by oral therapy with a dose of 250 mg once-daily dosing regimen for a total period of treatment of 7 days. The time it takes to make the transition to oral therapy must be decided by the physician depending on the clinical response.</p><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p>The same dosage regimen can be applied to elderly patients.</p><p>Since elderly patients are more susceptible to developing cardiac arrhythmia, particular caution is recommended due to the risk of developing cardiac arrhythmia and torsade de pointes (see Section 4.4).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>The efficacy and tolerability of ZITHROMAX powder for solution for infusion in the treatment of infections in children and adolescents under the age of 16 years have not been established. In controlled clinical trials azithromycin by oral administration was administered to paediatric patients (aged from 6 months to 16 years). For information on the use of azithromycin in the treatment of paediatric patients, see the Summary of Product Characteristics of the oral formulations of the azithromycin.</p><p>&nbsp;</p><p><u>Renal Impairment</u></p><p>No dose adjustment is required for patients with a glomerular filtration rate (GFR) of 10 - 80 mL/min; however, caution is necessary for patients with a GFR of &lt; 10 mL/min (see Sections 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Hepatic Impairment</u></p><p>No dose adjustment is required for patients with mild to moderate hepatic impairment (see Sections 4.4 and 5.2).</p><p>&nbsp;</p><p><strong><u>Method of administration</u></strong></p><p>ZITHROMAX powder for solution for infusion after reconstitution and dilution should be administered by intravenous infusion.</p><p>The concentration of the solution and the duration of the infusion must be equal to: 1 mg/mL in 3 hours or 2 mg/mL in 1 hour.</p><p>&nbsp;</p><p><strong>ZITHROMAX powder for solution for infusion should not be administered as a bolus or intramuscularly (see Sections 4.4 and 6.6).</strong></p><p>&nbsp;</p><p><u>Preparation of the solution for intravenous administration </u><u>(see also Section 6.6)</u></p><p>&nbsp;</p><p><u>Reconstitution</u></p><p>The initial solution must be prepared by adding 4.8 mL of water for injections in the vial containing the powder. Shake the vial until the powder has completely dissolved. Using a standard 5-mL syringe is recommended to take the exact volume of 4.8 mL of sterile water for injections. 1 mL of reconstituted solution contains 100 mg of azithromycin.</p><p>The drugs to be administered via parenteral route must be carefully controlled to exclude the presence of particulate in the solution. If suspended particles can be seen, the solution should be discarded.</p><p>The reconstituted solution must be diluted prior to administration by following the instructions below.</p><p>&nbsp;</p><p><u>Dilution</u></p><p>In order to obtain a concentration of azithromycin equal to 1.0-2.0 mg/mL, remove 5 mL of the reconstituted solution from the vial (concentration of 100 mg/mL), adding it to the appropriate volume of one of the solvents mentioned in Section 6.6.</p><p><u>&nbsp;</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><u>Final concentration of the solution for infusion</u></p></td><td style="vertical-align:top"><p><u>Solvent volume</u></p></td></tr><tr><td style="vertical-align:top"><p>1.0 mg/mL</p></td><td style="vertical-align:top"><p>500 mL</p></td></tr><tr><td style="vertical-align:top"><p>2.0 mg/mL</p></td><td style="vertical-align:top"><p>250 mL</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>The intravenous administration of a 500 mg dose of azithromycin, diluted according to the instructions must be performed within a period of not less than 60 minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active ingredient, to erythromycin, any other macrolide or ketolide antibiotics, or any other excipients listed in paragraph 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>As for erythromycin and other macrolides serious rare allergic reactions have been reported, including angioneurotic oedema and anaphylaxis (rarely fatal), dermatological reactions including acute generalized exanthematous pustulosis (AGEP), Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (rarely fatal) and rash with eosinophilia and systemic symptoms (DRESS). Some of these reactions associated with Zithromax have caused recurring symptoms and have required an observation period and prolonged treatment.</p><p>&nbsp;</p><p>If there is an allergic reaction, the administration of the medicinal product must be discontinued and adequate therapy started. Physicians should be aware of the fact that when the symptomatic therapy is suspended allergic symptoms may occur.</p><p><u>&nbsp;</u></p><p><u>Hepatotoxicity</u></p><p>Azithromycin must be used with caution in patients with serious liver disease since its primary route of elimination is the liver. With azithromycin, there have been reports of hepatic impairment, hepatitis, cholestatic jaundice, hepatic necrosis and fulminant hepatic failure, potentially caused by hepatic impairment, some of which had fatal results (see Section 4.8). A few patients may have had previous hepatic diseases or may have taken other hepatotoxic medicinal products. If signs and symptoms of hepatic dysfunction develop, such as rapid appearance of asthaenia associated with jaundice, dark urine, bleeding or hepatic encephalopathy, diagnostic analysis/exams must be run on hepatic function immediately.</p><p>Immediately suspend treatment with azithromycin if any signs of hepatic dysfunction develop.</p><p>&nbsp;</p><p><u>Infantile hypertrophic pyloric stenosis (IHPS)</u></p><p>As a result of the use of azithromycin in infants (treatment up to 42nd day of life), infantile hypertrophic pyloric stenosis (IHPS) has been reported. Parents and health operators must be told to contact their physician if vomiting or irritability occurs after eating.</p><p>&nbsp;</p><p><u>Ergotamine Derivatives</u></p><p>Co-administration of macrolide antibiotics in patients being treated with ergotamine derivatives has precipitated convulsive ergotism. There are no data currently available on the possibility of interaction between ergotamine and azithromycin. However, due to the theoretical possibility of ergotism, azithromycin and ergotamine must not be co-administered.</p><p>&nbsp;</p><p>As with all other antibiotic preparations, it is recommended to carefully monitor for any development of super infections with resistant micro-organisms including fungi.</p><p>&nbsp;</p><p><u>Diarrhoea associated with <em>Clostridium difficile</em></u></p><p>As with almost all antibiotics, including azithromycin, there have been reports of diarrhoea associated with <em>Clostridium difficile</em> (CDAD), the severity of which can vary from mild diarrhoea to fatal colitis. Treatment with antibiotics alters the normal flora of the colon and results in excessive growth of <em>C. difficile.</em></p><p>&nbsp;</p><p><em>C. difficile</em> produces toxins A and B, which contribute to the development of diarrhoea. The strains of <em>C. difficile</em> that produce excess toxins cause an increase in morbidity and mortality rates as these infections are usually refractory to antibacterial therapy and often require a colectomy. The possibility of diarrhoea associated with <em>C. difficile</em> must be considered in all patients who develop diarrhoea after a treatment with antibiotics. A detailed patient history is also necessary because cases of diarrhoea associated with <em>C. difficile</em> have been reported over two months after the administration of antibiotics.</p><p>&nbsp;</p><p><u>Renal Impairment</u></p><p>In patients with a GFR of &lt; 10 mL/min a 33% increase in systemic exposure to azithromycin was observed (see Section 5.2).</p><p>&nbsp;</p><p><u>Prolonged QT interval</u></p><p>In treatment with macrolides, including azithromycin, a prolonged cardiac repolarisation and QT interval were found using ECG, with the risk of developing cardiac arrhythmia and torsade de pointes (see Section 4.8). Therefore, given that the following situations can cause an increase in the risk of ventricular arrhythmias (including torsade de pointes) that can lead to cardiac arrest, azithromycin should be administered with caution in patients who have concomitant proarrhythmic conditions (especially women and elderly patients).</p><p>Prescribers must take into account the risk of the prolongation of the QT interval, which can be fatal, in assessing the risks and benefits of azithromycin in groups of patients at risk, such as:</p><p>&sect;&nbsp; Patients with congenital or documented prolonged QT interval.</p><ul><li>Patients under treatment with other active ingredients that prolong the QT interval such as class IA (quinidine and procainamide) and class III anti-arrhythmics (dofetilide, amiodarone and sotalol), cisapride and terfenadine, antipsychotic drugs such as pimozide, antidepressants such as citalopram, fluoroquinolones such as moxifloxacin, levofloxacin and chloroquine.</li><li>Patients with electrolyte changes, especially in cases of hypopotassaemia and hypomagnesaemia.</li><li>Patients with clinically significant bradycardia, cardiac arrhythmia or severe heart failure.</li></ul><p>&sect;&nbsp; Women and elderly patients who may demonstrate greater sensitivity to the (drug-related) effects of alteration of the QT interval.</p><p>&nbsp;</p><p>In patients being treated with azithromycin, there have been reports of exacerbation in symptoms of myasthenia gravis and initial development of myasthenic syndrome (see paragraph 4.8).</p><p>&nbsp;</p><p>The safety and efficacy of azithromycin for intravenous administration in the treatment of paediatric infections have not been established.</p><p>&nbsp;</p><p>ZITHROMAX powder for solution for infusion has to be reconstituted and diluted by following the instructions and must be administered with infusions lasting at least 60 minutes. <strong>Not for bolus injection or intramuscularly (see Sections 4.2 and 6.6).</strong></p><p>&nbsp;</p><p>ZITHROMAX 500 mg powder for solution for injection contains 114 mg of sodium per each vial, equivalent to 5,7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>Zithromax 500 mg /5 ml powder for solution for infusion may be further prepared for administration with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antacids</u></p><p>In a pharmacokinetic study on the effects caused by co-administration of antacids and oral azithromycin, no effects were detected on the bioavailability of azithromycin, even though a decrease of approximately 25% was observed in maximum serum concentrations. Therefore, patients being treated with oral azithromycin and antacids containing magnesium and aluminium must not take the two drugs concomitantly. The administration of oral antacids should not alter the characteristics of azithromycin administered intravenously.</p><p><u>&nbsp;</u></p><p><u>Cetirizine</u></p><p>In healthy volunteers, the concomitant administration of a 5-day regimen of azithromycin and 20&nbsp;mg of steady state cetirizine did not show any pharmacokinetic interactions or significant alterations in the QT interval.</p><p><u>&nbsp;</u></p><p><u>Didanosine</u></p><p>It was observed that co-administration of daily doses of azithromycin 1,200 mg/day and didanosine 400 mg/day in six HIV-positive patients did not have any effect on the steady state pharmacokinetics of didanosine compared to placebo.</p><p><u>&nbsp;</u></p><p><u>Digoxin and colchicine (P-glycoprotein substrates)</u></p><p>There have been reports that the administration of macrolide antibiotics, including azithromycin with P-glycoprotein substrates such as digoxin, has caused an increase in the blood serum levels of P-glycoprotein substrates. Therefore, the possibility of an increase in digoxin blood serum levels must be carefully considered when co-administering azithromycin and P-glycoprotein substrates, such as digoxin. Clinical monitoring is required both during and after interruption of azithromycin treatment, as well as monitoring for possible increases in digoxin levels.</p><p><u>&nbsp;</u></p><p><u>Zidovudine</u></p><p>The administration of individual 1,000&nbsp;mg doses and multiple 1,200&nbsp;mg or 600&nbsp;mg doses of azithromycin did not substantially modify the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, the administration of azithromycin resulted in increased concentrations of phosphorylated zidovudine, its clinically active metabolite, in the peripheral blood mononuclear cells.&nbsp; The clinical importance of this data is not clear, but it may still render benefits to the patient.</p><p>&nbsp;</p><p>Azithromycin does not significantly interact with the cytochrome P450 hepatic system. It is not deemed to be involved in pharmacokinetic interactions as found with erythromycin and other macrolides. &nbsp;Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin.</p><p>&nbsp;</p><p><u>Ergotamine</u></p><p>Due to the potential onset of convulsive ergotism, concomitant use of azithromycin and ergotamine derivatives is not recommended (see Section 4.4).</p><p>&nbsp;</p><p>Pharmacokinetic studies have been conducted between azithromycin and the following drugs, for which significant metabolic activity was noted and mediated by cytochrome P450.</p><p><u>&nbsp;</u></p><p><u>HMG-CoA Reductase Inhibitors (Statins)</u></p><p>The concomitant administration of atorvastatin (10 mg/day) and azithromycin (500 mg/day) did not alter the plasma concentrations of atorvastatin (based on an HMG-CoA reductase inhibition assay) and thus did not cause alterations of HMG-CoA reductase activity. However, post-marketing cases of rhabdomyolysis have been reported in patients treated with azithromycin and statins.</p><p>&nbsp;</p><p><u>Carbamazepine</u></p><p>During an interaction study conducted in healthy volunteers, no significant effects were observed on plasma levels of carbamazepine or its active metabolite in patients who were taking azithromycin concomitantly.</p><p><u>&nbsp;</u></p><p><u>Cimetidine</u></p><p>During a pharmacokinetic study conducted to assess the effects of a single dose of cimetidine administered 2&nbsp;hours after azithromycin, no alterations were noted in azithromycin pharmacokinetics.</p><p><u>&nbsp;</u></p><p><u>Cyclosporine</u></p><p>In a pharmacokinetic study conducted in healthy volunteers administered an oral dose of 500&nbsp;mg/day of azithromycin for 3 days and then a single oral dose of 10 mg/kg of cyclosporine, significant increases in the C<sub>max</sub> and AUC<sub>0-5</sub> values for cyclosporine were observed. Therefore, any co-administration of these two drugs requires caution. If co-administration of these two drugs is absolutely necessary, cyclosporine levels must be closely monitored and the dose of cyclosporine must be adjusted as needed.</p><p>&nbsp;</p><p><u>Efavirenz</u></p><p>Co-administration of a single daily dose of azithromycin (600 mg) and efavirenz (400 mg) for seven days did not cause any clinically significant pharmacokinetic interaction.</p><p>&nbsp;</p><p><u>Fluconazole</u></p><p>Co-administration of a single dose of azithromycin (1,200 mg) did not alter the pharmacokinetics of a single dose of fluconazole (800 mg). The total exposure time and half-life of azithromycin were not influenced by co-administration of fluconazole, although there was a clinically insignificant decrease in C<sub>max</sub> (18%).</p><p>&nbsp;</p><p><u>Indinavir</u></p><p>Concomitant administration of a single dose of azithromycin (1,200 mg) did not show a statistically significant effect on the pharmacokinetics of indinavir administered three times a day for 5 days at doses of 800 mg.</p><p><u>&nbsp;</u></p><p><u>Methylprednisolone</u></p><p>A pharmacokinetic study conducted on healthy volunteers showed that azithromycin does not significantly influence methylprednisolone pharmacokinetics.</p><p><u>&nbsp;</u></p><p><u>Midazolam</u></p><p>In healthy volunteers, concomitant administration of azithromycin 500 mg/day for 3 days did not cause any clinically significant changes in the pharmacokinetics or pharmacodynamics of a single dose of midazolam 15 mg.</p><p>&nbsp;</p><p><u>Nelfinavir</u></p><p>Co-administration of azithromycin (1,200 mg) and steady state nelfinavir (750 mg three times per day) caused an increase in the concentrations of azithromycin.&nbsp; No clinically significant adverse reactions were observed and no dose adjustment was necessary.</p><p><u>&nbsp;</u></p><p><u>Rifabutin</u></p><p>Concomitant administration of azithromycin and rifabutin does not change the serum concentrations of the two drugs.</p><p>Cases of neutropenia have been observed in some patients taking the two drugs concomitantly; although it is known that rifabutin can cause neutropenia, it is not possible to verify a causal relation between the aforementioned episodes of neutropenia and the association of rifabutin and azithromycin (see Section 4.8).</p><p>&nbsp;</p><p><u>Sildenafil</u></p><p>In healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg/day for 3 days) on the AUC and C<sub>max </sub>of sildenafil or its major circulating metabolite.</p><p><u>&nbsp;</u></p><p><u>Theophylline</u></p><p>Co-administration of azithromycin and theophylline to healthy volunteers did not show any clinically significant interaction between the two drugs.</p><p>&nbsp;</p><p><u>Terfenadine</u></p><p>Pharmacokinetic studies did not show any interactions between azithromycin and terfenadine. Some rare cases were reported in which the possibility of this interaction could not be completely ruled out; however, there is no scientific evidence that the interaction occurred.</p><p><u>&nbsp;</u></p><p><u>Triazolam</u></p><p>In 14 healthy volunteers, concomitant administration of 500&nbsp;mg of azithromycin on Day 1 and 250&nbsp;mg on Day 2 and 0.125&nbsp;mg of triazolam on Day 2 did not have significant effects on the pharmacokinetic variables of triazolam compared to triazolam and placebo.</p><p><u>&nbsp;</u></p><p><u>Trimethoprim/Sulfamethoxazole</u></p><p>After concomitant administration of trimetoprim/sulfamethoxazole (160 mg/800 mg) and azithromycin (1,200 mg) for 7 days, no significant effect was found on peak concentrations, exposure time, or urinary excretion of both trimetoprim and sulfamethoxazole on Day 7. Azithromycin serum concentrations were similar to those found in other studies.</p><p><u>&nbsp;</u></p><p><u>Coumarin-type Oral Anticoagulants</u></p><p>In a pharmacokinetic study conducted on healthy volunteers, it was observed that azithromycin did not modify the anticoagulant effect of a single 15 mg dose of warfarin.</p><p>During the post-marketing phase, cases of increased anticoagulant action were reported following co-administration of azithromycin and coumarin-type oral anticoagulants. Even though a causal relationship has not been established, it is recommended to re-evaluate the frequency of monitoring prothrombin time when administering azithromycin to patients receiving coumarin-type anticoagulants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>4.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>As for erythromycin and other macrolides serious rare allergic reactions have been reported, including angioneurotic oedema and anaphylaxis (rarely fatal), dermatological reactions including acute generalized exanthematous pustulosis (AGEP), Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (rarely fatal) and rash with eosinophilia and systemic symptoms (DRESS). Some of these reactions associated with Zithromax have caused recurring symptoms and have required an observation period and prolonged treatment.</p><p>&nbsp;</p><p>If there is an allergic reaction, the administration of the medicinal product must be discontinued and adequate therapy started. Physicians should be aware of the fact that when the symptomatic therapy is suspended allergic symptoms may occur.</p><p><u>&nbsp;</u></p><p><u>Hepatotoxicity</u></p><p>Azithromycin must be used with caution in patients with serious liver disease since its primary route of elimination is the liver. With azithromycin, there have been reports of hepatic impairment, hepatitis, cholestatic jaundice, hepatic necrosis and fulminant hepatic failure, potentially caused by hepatic impairment, some of which had fatal results (see Section 4.8). A few patients may have had previous hepatic diseases or may have taken other hepatotoxic medicinal products. If signs and symptoms of hepatic dysfunction develop, such as rapid appearance of asthaenia associated with jaundice, dark urine, bleeding or hepatic encephalopathy, diagnostic analysis/exams must be run on hepatic function immediately.</p><p>Immediately suspend treatment with azithromycin if any signs of hepatic dysfunction develop.</p><p>&nbsp;</p><p><u>Infantile hypertrophic pyloric stenosis (IHPS)</u></p><p>As a result of the use of azithromycin in infants (treatment up to 42nd day of life), infantile hypertrophic pyloric stenosis (IHPS) has been reported. Parents and health operators must be told to contact their physician if vomiting or irritability occurs after eating.</p><p>&nbsp;</p><p><u>Ergotamine Derivatives</u></p><p>Co-administration of macrolide antibiotics in patients being treated with ergotamine derivatives has precipitated convulsive ergotism. There are no data currently available on the possibility of interaction between ergotamine and azithromycin. However, due to the theoretical possibility of ergotism, azithromycin and ergotamine must not be co-administered.</p><p>&nbsp;</p><p>As with all other antibiotic preparations, it is recommended to carefully monitor for any development of super infections with resistant micro-organisms including fungi.</p><p>&nbsp;</p><p><u>Diarrhoea associated with <em>Clostridium difficile</em></u></p><p>As with almost all antibiotics, including azithromycin, there have been reports of diarrhoea associated with <em>Clostridium difficile</em> (CDAD), the severity of which can vary from mild diarrhoea to fatal colitis. Treatment with antibiotics alters the normal flora of the colon and results in excessive growth of <em>C. difficile.</em></p><p>&nbsp;</p><p><em>C. difficile</em> produces toxins A and B, which contribute to the development of diarrhoea. The strains of <em>C. difficile</em> that produce excess toxins cause an increase in morbidity and mortality rates as these infections are usually refractory to antibacterial therapy and often require a colectomy. The possibility of diarrhoea associated with <em>C. difficile</em> must be considered in all patients who develop diarrhoea after a treatment with antibiotics. A detailed patient history is also necessary because cases of diarrhoea associated with <em>C. difficile</em> have been reported over two months after the administration of antibiotics.</p><p>&nbsp;</p><p><u>Renal Impairment</u></p><p>In patients with a GFR of &lt; 10 mL/min a 33% increase in systemic exposure to azithromycin was observed (see Section 5.2).</p><p>&nbsp;</p><p><u>Prolonged QT interval</u></p><p>In treatment with macrolides, including azithromycin, a prolonged cardiac repolarisation and QT interval were found using ECG, with the risk of developing cardiac arrhythmia and torsade de pointes (see Section 4.8). Therefore, given that the following situations can cause an increase in the risk of ventricular arrhythmias (including torsade de pointes) that can lead to cardiac arrest, azithromycin should be administered with caution in patients who have concomitant proarrhythmic conditions (especially women and elderly patients).</p><p>Prescribers must take into account the risk of the prolongation of the QT interval, which can be fatal, in assessing the risks and benefits of azithromycin in groups of patients at risk, such as:</p><p>&sect;&nbsp; Patients with congenital or documented prolonged QT interval.</p><ul><li>Patients under treatment with other active ingredients that prolong the QT interval such as class IA (quinidine and procainamide) and class III anti-arrhythmics (dofetilide, amiodarone and sotalol), cisapride and terfenadine, antipsychotic drugs such as pimozide, antidepressants such as citalopram, fluoroquinolones such as moxifloxacin, levofloxacin and chloroquine.</li><li>Patients with electrolyte changes, especially in cases of hypopotassaemia and hypomagnesaemia.</li><li>Patients with clinically significant bradycardia, cardiac arrhythmia or severe heart failure.</li></ul><p>&sect;&nbsp; Women and elderly patients who may demonstrate greater sensitivity to the (drug-related) effects of alteration of the QT interval.</p><p>&nbsp;</p><p>In patients being treated with azithromycin, there have been reports of exacerbation in symptoms of myasthenia gravis and initial development of myasthenic syndrome (see paragraph 4.8).</p><p>&nbsp;</p><p>The safety and efficacy of azithromycin for intravenous administration in the treatment of paediatric infections have not been established.</p><p>&nbsp;</p><p>ZITHROMAX powder for solution for infusion has to be reconstituted and diluted by following the instructions and must be administered with infusions lasting at least 60 minutes. <strong>Not for bolus injection or intramuscularly (see Sections 4.2 and 6.6).</strong></p><p>&nbsp;</p><p>ZITHROMAX 500 mg powder for solution for injection contains 114 mg of sodium per each vial, equivalent to 5,7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>Zithromax 500 mg /5 ml powder for solution for infusion may be further prepared for administration with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that azithromycin affects the ability of patients to drive vehicles or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The table below lists the side effects identified during clinical studies and post-marketing surveillance, and they are subdivided based on system organ class and frequency. The possible adverse reactions identified during post-marketing surveillance are shown in italics. Frequency is defined using the following parameters: Very common (&ge; 1/10); Common (&ge; 1/100, &lt; 1/10); Uncommon (&ge; 1/1,000, &lt; 1/100); Rare (&ge; 1/10,000, &lt; 1/1,000); Very Rare (&lt; 1/10,000); Not known (frequency cannot be defined based on available data). Possible side effects are listed in order of decreasing severity within each frequency classification.</p><p>&nbsp;</p><p><strong>Adverse reactions with possible or probable correlation to azithromycin based on the results of clinical studies and post-marketing surveillance.</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Infections and infestations </strong></p></td><td style="vertical-align:top"><p>Candidiasis, vaginal infection, pneumonia, fungal infection, bacterial infection, pharyngitis, gastroenteritis, respiratory disorders, rhinitis, oral candidiasis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomembranous colitis</em> (see par. 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Leukopaenia, neutropaenia, eosinophilia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Thrombocytopaenia, haemolytic anaemia</em></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p><em>Angiooedema, hypersensitivity</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Anaphylactic reaction </em>(see Sec. 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top"><p>Nervousness, insomnia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><em>Aggression, anxiety,</em> delirium, hallucinations</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness, somnolence, dysgeusia, paraesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Syncope, convulsions, </em>hypoaesthesia, <em>psychomotor hyperactivity, anosmia, ageusia, parosmia,</em></p><p><em>Myasthenia gravis </em>(see Sec. 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>Vision impairment</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Ear disorders, vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hearing impairment including deafness and/or tinnitus</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Torsade de pointes </em>(see Sec. 4.4), <em>arrhythmia</em> (see par. 4.4<em>) including ventricular tachycardia, prolonged QT interval on the electrocardiogram </em>(see Sec. 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hot flashes</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Hypotension</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>Dyspnoea, epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation, flatulence, dyspepsia, gastritis, dysphagia, abdominal distension, dry mouth, eructation, mouth ulceration, salivary hypersecretion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Pancreatitis, tongue discolouration</em></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Impaired hepatic function, <em>cholestatic jaundice</em></p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatic failure</em> <em>(rarely fatal)</em> (see Sec. 4.4),<em> fulminant hepatitis, hepatic necrosis</em></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash, pruritus, urticaria, dermatitis, dry skin, hyperhidrosis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reaction, <em>acute generalised exanthematous pustulosis (AGEP)&sect;,</em></p><p><em>Drug rash with eosinophilia and systemic symptoms (DRESS)&sect; </em></p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome, <em>toxic epidermal necrolysis, erythema multiforme </em></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Osteoarthritis, myalgia, back pain, neck pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><em>Dysuria, renal pain</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><em>Acute renal insufficiency, interstitial nephritis</em></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive System and Breast Disorders</strong></p></td><td style="vertical-align:top"><p>Metrorrhagia, testicular disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Oedema, asthaenia, malaise, fatigue, facial oedema, chest pain, pyrexia, pain, peripheral oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pain at injection site*, inflammation at injection site*</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Diagnostic tests</strong></p></td><td style="vertical-align:top"><p>Decrease in lymphocyte count, increase in eosinophil count, decrease in blood bicarbonate, increase in basophils, increase in monocytes, increase in neutrophils</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Increase in aspartate aminotransferase (AST), increase in alanine aminotransferase (ALT), increase in blood bilirubin, increase in blood urea, increase in blood creatinine, abnormal blood potassium, increase in blood alkaline phosphatase, increase in chloride levels, increase in glucose, increase in platelets, decrease in haematocrit, increase in blood bicarbonate, abnormal sodium levels</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury and Poisoning</strong></p></td><td style="vertical-align:top"><p>Post-procedural complications</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p><sup>&sect;</sup><em> </em>Frequency ADR represented by the estimated upper limit of the 95% confidence interval calculated using the &quot;Rule of 3&quot;</p><p>* only for the powder for solution for infusion</p><p>&nbsp;</p><p><strong>Adverse reactions possibly or probably related to Mycobacterium Avium Complex prophylaxis and treatment based on clinical trial experience and post-marketing surveillance. These adverse reactions <u>differ</u> from those reported with immediate release or prolonged release formulations, in kind or in frequency:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong>(&ge; 1/100, &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon </strong></p><p><strong>(&ge; 1/1,000, &lt; 1/100)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>Paraesthesia</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Hypoesthesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision impairment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deafness</p></td><td style="vertical-align:top"><p>Impaired hearing</p><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Abdominal pain</p><p>Nausea</p><p>Flatulence</p><p>Abdominal discomfort</p><p>Loose stools</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p><p>Photosensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Asthaenia</p><p>Malaise</p></td></tr></tbody></table><p>&nbsp;</p><p>Reporting of suspected adverse reactions.</p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows constant monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects reported with doses greater than those recommended were similar to those reported with normal doses. In case of overdose, the appropriate general symptomatic and support measures are indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterial agents for systemic use: macrolides, ATC code: J 01FA10.</p><p>&nbsp;</p><p>Azithromycin is the first drug in a sub-class of macrolide antibiotics called azalides, and is chemically different from erythromycin. It is chemically derived from the insertion of a nitrogen atom into the lactone ring of the erythromycin A. Its chemical name is: 9-deoxy-9a-aza-9a-methyl-9a-homoerithromycin A. The molecular weight is 749.0.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Azithromycin binds to the 23S rRNA of 50S ribosomal subunit. Azithromycin blocks protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit.</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p>The prolongation of the QT interval was studied in a randomized, placebo-controlled study in parallel groups on 116 healthy subjects who either took chloroquine (1,000 mg) alone or in combination with azithromycin (500 mg, 1,000 mg, 1,500 mg once a day). The coadministration with azithromycin resulted in an increase in QTc interval in a dose- and concentration-dependent way. Maximum increases in the QTcF compared with chloroquine monotherapy (whose differences observed with respect to the placebo vary in the range of between 18.4 and 35 ms) were on average (upper limit of the 95% confidence interval) 5 (10 ms), 7 (12 ms) and 9 (14) ms following the concomitant administration of 500 mg, 1,000 mg, 1,500 mg of azithromycin respectively.</p><p>&nbsp;</p><p><u>Mechanism of resistance</u></p><p>The two most frequently encountered mechanisms of resistance to macrolides, including azithromycin, are target modification (very often due to methylation of 23S rRNA) and active efflux. The occurrence of these resistance mechanisms varies from species to species, and within each species the frequency of resistance varies depending on the geographical location.</p><p>&nbsp;</p><p>The most important ribosomal modification that determines reduced binding of macrolides is post-transcriptional (N)- 6 demethylation of adenine at nucleotide A2058 (<em>E.coli</em> numbering system) of the 23S rRNA by the methylases codified by <em>erm</em> (erithromycin ribosomal methylase) genes.</p><p>Ribosomal modifications often determine cross resistance (MLSBphenotype) to other classes of antibiotics whose ribosomal binding sites overlap that of the macrolides: the lincosamides (including clindamycin), and the Type B streptogramins (which include, for example, the quinupristin component of quinupristin/dalfopristin). Different <em>erm</em> genes are present in different bacterial species, in particular streptococci and staphylococci. <sup>&nbsp;</sup>Susceptibility to macrolides can also be affected by less frequently encountered mutational changes in nucleotides A2058 and A2059, and at some other positions of 23S rRNA or in the large subunit ribosomal proteins L4 and L22.</p><p>&nbsp;</p><p>Efflux pumps occur in a number of species, including Gram-negatives, such as <em>Haemophilus influenzae </em>(where they may determine intrinsically higher minimum inhibitory concentrations [MICs]) and staphylococci. In streptococci and in enterococci, an efflux pump that recognizes macrolides measuring 14 and 15 atoms (including, respectively, erythromycin and azithromycin) is codified by mef (A) genes.</p><p>&nbsp;</p><p><strong><u>Method for Determining In Vitro Susceptibility of Bacteria to Azithromycin</u></strong></p><p><u>&nbsp;</u></p><p>Susceptibility testing should be conducted using standardised laboratory methods such as those described by the <em>Clinical and Laboratory Standards Institute</em> (CLSI). These include dilution methods (MIC determination) and disk susceptibility methods.</p><p>Both the CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) provide interpretative criteria for these methods.</p><p>Based on a number of studies, it is recommended that the <em>in vitro</em> activity of azithromycin be tested in ambient air to ensure physiological pH of the growth medium. Elevated CO<sub>2</sub> pressures, such as those used for streptococci and anaerobic bacteria, and occasionally for other species, results in a reduction in the pH of the medium. This has a greater adverse effect on the apparent potency of azithromycin than on that of other macrolides.</p><p>&nbsp;</p><p>EUCAST has also established the susceptibility breakpoints for azithromycin based on MIC determination. The EUCAST susceptibility criteria are listed in the following table.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><thead><tr><td colspan="4" style="vertical-align:top"><p>Susceptibility breakpoints for azithromycin</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>MIC (mg/L)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Resistant</p></td><td><p>&nbsp;</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><em>Staphylococcus</em> spp.</p></td><td style="vertical-align:top"><p>&pound;&nbsp;1</p></td><td style="vertical-align:top"><p>&gt; 2</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&pound;&nbsp;0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic b streptococcus <sup>a</sup></p></td><td style="vertical-align:top"><p>&pound;&nbsp;0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&pound;&nbsp;0.12</p></td><td style="vertical-align:top"><p>&gt; 4</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&pound;&nbsp;0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td style="vertical-align:top"><p>&pound;&nbsp;0.25</p></td><td style="vertical-align:top"><p>&gt; 0.5</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> includes groups A, B, C, G.<br />EUCAST&nbsp;=&nbsp;<em>European Committee on Antimicrobial Susceptibility Testing</em>; MIC&nbsp;=&nbsp;Minimum inhibitory concentration.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Antibacterial spectrum</u></p><p>The prevalence of acquired resistance may vary geographically and over time for selected species, and it is helpful to have local information on resistances, in particular when treating serious infections. If necessary, expert advice should be requested if the local prevalence of resistant strains is such that the usefulness of agents, at least in certain types of infections, is disputable.</p><p>&nbsp;</p><p>Azithromycin shows cross resistance with erythromycin resistant gram-positive germs. As described above, some ribosomal modifications determine cross resistance with other classes of antibiotics whose ribosomal binding sites overlap that of the macrolides: the lincosamides (including clindamycin), and the Type B streptogramins (which include, for example, the quinupristin component of quinupristin/dalfopristin). Over the course of time, a decrease has been noted in macrolide susceptibility, in particular in <em>Streptococcus pneumoniae and in Staphylococcus aureus, </em>and has also been observed in <em>viridans </em>group streptococci and in<em> Streptococcus agalactiae.</em></p><p>&nbsp;</p><p>Organisms that are commonly susceptible to azithromycin include:</p><p>Aerobic and facultative gram-positive bacteria (erithromycin-susceptible isolates): <em>S.&nbsp;aureus</em>, <em>Streptococcus agalactiae</em>*, <em>S.&nbsp;pneumoniae</em>*, <em>Streptococcus pyogenes</em>*, other haemolytic b streptococci (groups C, F, G), <em>viridans</em> group streptococci.<em> </em>Macrolide-resistant germs are found relatively frequently among aerobic and facultative gram-positive bacteria, in particular among methicillin-resistant <em>S. aureus</em> (MRSA) and penicillin-resistant <em>S. pneumoniae</em> (PRSP).</p><p>&nbsp;</p><p>Aerobic and facultative gram-negative bacteria:<em> Bordetella pertussis</em>, <em>Campylobacter jejuni</em>, <em>Haemophilus ducreyi</em>*, <em>Haemophilus influenzae</em>*, <em>Haemophilus parainfluenzae</em>*, <em>Legionella pneumophila</em>, <em>Moraxella catarrhalis</em>*, and <em>Neisseria gonorrhoeae</em>*. <em>Pseudomonas</em>&nbsp;spp. and the majority of <em>Enterobacteriaceae</em> are inherently resistant to azithromycin, although azithromycin has been used to treat <em>Salmonella enterica</em> infections.</p><p>&nbsp;</p><p>Anaerobes: <em>Clostridium perfringens, </em><em>Peptostreptococcus&nbsp;spp</em>. and <em>Prevotella bivia</em>.</p><p>&nbsp;</p><p>Other bacterial species:<em> Borrelia burgdorferi</em>, <em>Chlamydia trachomatis</em>, <em>Chlamydophila pneumoniae</em>*, <em>Mycoplasma pneumoniae</em>*, <em>Treponema pallidum</em>, and <em>Ureaplasma urealyticum</em>.</p><p>&nbsp;</p><p>Opportunistic pathogens associated with HIV infection. MAC*, and the eukaryote micro-organisms <em>Pneumocystis jirovecii</em> and <em>Toxoplasma gondii</em>.</p><p>&nbsp;</p><p>*The efficacy of azithromycin against the described species has been demonstrated in clinical studies</p><p>&nbsp;</p><p><u>Clinical pharmacology</u></p><p>&nbsp;</p><p><u>Treatment of community-acquired pneumonia</u></p><p>In a non-comparative, open-label study carried out on patients suffering from community-acquired pneumonia, subjects were administered azithromycin for intravenous infusion (for 2-5 days) followed by azithromycin orally (to complete a total treatment period of 7-10 days). Among evaluable patients, the clinical success rates (recovery and improvement) were equal to 88% (74/84) after 10-14 days from the end of the therapy and 86% (73/85) after 4 to 6 weeks.</p><p>&nbsp;</p><p>In a randomised, open-label, comparative study between azithromycin (intravenously followed by oral therapy) and cefuroxime (intravenously followed by oral therapy, in combination with erythromycin or not) in community-acquired pneumonia therapy, no statistically significant differences were observed between the two treatments.</p><p>&nbsp;</p><p>In these two studies an overall recovery percentage of 84% (16/19) was found in patients with positive serology for <em>Legionella pneumophila. </em>Furthermore, in an open-label, non-comparative study, patients with <em>Legionella pneumophila </em>(serogroup 1) with the diagnosis made by a specific urinary antigen test were treated with azithromycin intravenously followed by azithromycin orally positive. After 10-14 days of therapy, clinical recovery was achieved in 16 of 17 of the evaluable patients and after 4-6 weeks, 20 patients out of 20 had recovered.</p><p>&nbsp;</p><p><u>Treatment of pelvic inflammatory disease</u></p><p>The results of an open-label study indicate that three therapeutic regimens of pelvic inflammatory disease (azithromycin vs. azithromycin/metronidazole and vs. doxycycline, metronidazole, cefoxitin and probenecid) are comparable both from the point of view of efficacy and safety. In another open-label, comparative study, patients suffering from pelvic inflammatory disease were treated with azithromycin IV/oral vs. azithromycin IV in combination with metronidazole IV/oral and vs. doxycycline in combination with amoxicillin - clavulanic acid IV/oral. These regimens were shown to be comparable in terms of efficacy and safety. The data reported from these studies show overall clinical success (recovery and improvement) &ge; 97% in all treatment groups, with a &ge; 96% percentage of pathogens eradicated at the end of the therapy. In the follow-up, the percentage of pathogens eradicated was &ge; 90%.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Following the assessment of studies conducted on children, because non-inferiority has not been established with respect to the antimalarial drugs recommended in the treatment of uncomplicated malaria, the use of azithromycin is not recommended for the treatment of malaria, either as monotherapy or in combination with chloroquine or artemisinin-based drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption/Distribution</u></p><p>In humans after oral administration, azithromycin spreads quickly and extensively throughout the body with a bioavailability of about 37%. The time required to obtain peak plasma levels is 2-3 hours.</p><p>In hospitalised patients with community-acquired pneumonia who received a once-daily dosing regimen of 500 mg of azithromycin for infusion (for 1 hour, concentration equal to 2 mg/mL) for 2-5 days, the average C<sub>max</sub> reached was 3.63 &plusmn; 1.60 g/mL, the threshold level reached after 24 hours was 0.20 &plusmn; 0.15 g/mL and the AUC<sub>24</sub> was equal to 9.60 &plusmn; 4.80 g h/mL.</p><p>In healthy volunteers who received 500 mg of azithromycin for infusion (for 3 hours, concentration equal to 1 mg/mL), the average C<sub>max</sub> reached was 1.14 &plusmn; 0.14 g/mL, the threshold level reached after 24 hours was 0.18 &plusmn; 0.02 g/mL and the AUC<sub>24</sub> was equal to 8.03 &plusmn; 0.86 g h/mL.</p><p>In animal studies, high concentrations of azithromycin were observed inside phagocyte cells. In experimental models, higher concentrations of azithromycin were released by activated phagocytes than by non-activated phagocytes. In the animal model, this phenomena causes high concentrations of azithromycin at the infection site.</p><p>&nbsp;</p><p>Pharmacokinetic studies in humans have shown higher azithromycin tissue levels compared to plasma levels (up to 50 times the maximum concentrations observed in plasma) indicating, therefore, that the drug is highly bound to tissues. Concentrations in tissues such as lung, tonsil, and prostate, exceed MIC<sub>90</sub> values for common pathogens after a single administration of 500 mg of azithromycin.</p><p>High concentrations of azithromycin have been found in gynaecological tissues 96 hours after a single oral administration of 500 mg.</p><p><u>&nbsp;</u></p><p><u>Biotransformation/Elimination</u></p><p>The terminal plasma half-life time closely reflects the tissue depletion half-life time (from 2 to 4 days). In a study with multiple doses conducted on 12 healthy volunteers with a dosage of 500 mg intravenously (1 mg/mL in an hour) for 5 days, the amount of unchanged azithromycin eliminated in the urine in 24 hours was equal to about 11% after the 1st dose and approximately 14% after the 5th dose. These values are higher than the rate of 6% of unchanged drug reported for azithromycin administered orally. Biliary elimination is the primary route of unchanged drug elimination after oral administration.</p><p>Very elevated concentrations of unchanged drug were found in human bile along with 10 metabolites formed by the N‑ and O-demethylation processes, by hydroxylation of the desosamine and the glyconic ring and by cleavage of the cladinosium-conjugates. Comparison of HPLC and microbiological assays in tissues suggests that metabolites play no part in the microbiological activity of azithromycin powder for solution for infusion.</p><p>&nbsp;</p><p><u>Pharmacokinetics in Special Patient Populations</u></p><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p>A study conducted in healthy volunteers highlighted that after a treatment period of 5 days, AUC values were slightly higher in elderly patients (&gt; 65 years) compared to younger patients (&lt; 40 years); however, because this data is not clinically significant, no dose adjustment is required.</p><p>&nbsp;</p><p><u>Renal Impairment</u></p><p>Following single oral administration of 1 gram of azithromycin, no pharmacokinetic effects were found in patients with a GFR of 10 - 80 mL/min. However, statistically significant differences were found in AUC values<sub>0-120 </sub>(8.8 mg-h/mL vs. 11.7 mg-h/mL), C<sub>max</sub> (1.0 mg/mL vs. 1.6 mg/mL) and CLr (2.3 mL/min/kg vs. 0.2 mL/min/kg) among the group with a GFR of &lt; 10 mL/min and a GFR of &gt; 80 ml/min.</p><p>&nbsp;</p><p><u>Hepatic Impairment</u></p><p>In patients with mild (Class A) and moderate (Class B) hepatic impairment, there was no evidence of significant changes in the blood pharmacokinetics of the azithromycin compared to patients with normal hepatic function. In these patients, elimination of azithromycin through urine seemed to increase, probably as compensation for reduced hepatic clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal studies conducted with elevated doses that exceeded 40 times the maximum dose used in clinical practice, it was found that azithromycin caused reversible phospholipidosis, generally without true toxicological consequences. The effect proved to be reversible with discontinuation of the azithromycin treatment. The significance of these results for animals as well as for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid, sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The reconstituted solution of azithromycin powder for solution for infusion should be diluted according to the instructions and with the compatible infusion solutions indicated in Section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

The reconstituted solution is chemically and physically stable for 24 hours if stored at temperatures no higher than 30°C. However, from a microbiological point of view, the product should be used immediately. If the solution is not used immediately, the people who use it need to check the storage times and conditions. However, it is advisable not to exceed 24 hours at temperatures of between 2 and 8°C, unless the reconstitution/dilution has taken place under validated and controlled aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A white to off-white cake powder in type I 10-mL glass vial with a closure comprising grey bromobutyl rubber stoppers and aluminium seal, containing 500 mg of active substance.</p><p>Each pack contain 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>ZITHROMAX powder for solution for infusion is contained in a disposable vial. The contents of the vial should be reconstituted with 4.8 mL of sterile water for injections (100 mg/mL of azithromycin). For administration, the required volume of the reconstituted solution is added to the compatible solution for infusion in order to obtain a solution of azithromycin with a concentration equal to 1.0-2.0 mg/mL.</p><p>&nbsp;</p><p>The drugs to be administered via parenteral route must be carefully controlled to exclude the presence of particulate in the solution. If suspended particles can be seen, the solution should be discarded.</p><p>&nbsp;</p><p>The chemical and physical stability after reconstitution has been demonstrated for 24 hours at 30&deg;C. Once diluted according to the instructions, the solution is stable from a chemical and physical point of view for 24 hours at temperatures equal to or lower than 30&deg;C or for 7 days if stored in a refrigerator (5&deg;C).</p><p>However, from a microbiological point of view, the product should be used immediately. If the suspension is not used immediately, the people who use it need to check the storage times and conditions that would normally not be longer than 24 hours at temperatures of between 2 and 8&deg;C, unless the reconstitution/dilution has taken place under validated and controlled aseptic conditions.</p><p>&nbsp;</p><p>The reconstituted solution must be diluted with one of the following solutions for infusion:</p><p>&nbsp;</p><p>Physiological solution (0.9% sodium chloride)</p><p>Physiological solution (0.45% sodium chloride)</p><p>Ringer&rsquo;s lactate</p><p>Glucose 5% in water</p><p>Glucose 5% in physiological solution (0.45% sodium chloride) with 20 mEq KCl</p><p>Glucose 5% in physiological solution (0.45% sodium chloride)</p><p>Glucose 5% in physiological solution (0.30% sodium chloride)</p><p>Glucose 5% in Ringer&rsquo;s lactate</p><p>&nbsp;</p><p>The intravenous administration of a 500 mg dose of azithromycin, diluted according to the instructions must take place within a period of not less than 60 minutes.</p><p>&nbsp;</p><p>ZITHROMAX powder for solution for infusion should not be administered as a bolus or intramuscularly.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Italia S.r.l, Via Isonzo 71, 04100 Latina, Italy

MANUFACUTRED AND PRIMARY PACKAGING BY
Pharmacia and Upjohn Company LLC
7000 Portage Rd.
Kalamazoo, Michigan
USA

PACKED & RELEASED BY
Fareva Amboise
Zone Industrielle
29 route des Industries
37530 Pocé-sur-Cisse
France

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>